Recombinant CD40-ligand

Summary

Recombinant CD40‑ligand (rCD40L, also called CD154) is a laboratory‑produced version of the CD40‑binding cytokine that normally mediates T‑cell help to B cells and other immune cells. It is used experimentally to trigger B‑cell proliferation, class‑switching, and T‑cell activation, and has been explored as an immunomodulatory agent in conditions such as X‑linked hyper‑IgM syndrome, chronic lymphocytic leukemia, and neuroblastoma models.

Mechanism of Action

rCD40L binds the CD40 receptor on B cells, dendritic cells, macrophages and some tumor cells. This interaction up‑regulates surface MHC‑II, CD23, CD69 and IL‑2Rα, providing a co‑stimulatory signal that drives proliferation, immunoglobulin class switching and cytokine production (IL‑2, IFN‑γ, TNF‑α). In tumor cells, CD40 engagement can trigger caspase‑8‑dependent apoptosis. The ligand’s activity is enhanced when cross‑linked or combined with cytokines such as IL‑4 or IL‑5.

What the Research Shows

Early in‑vitro work showed that murine rCD40L activates resting B cells, increasing MHC‑II and CD23 expression and, together with IL‑4/IL‑5, promoting proliferation and isotype‑specific antibody secretion (1993, 1994). Recombinant ligand also augments T‑cell proliferation and activation marker expression (1994). Gene‑modified CLL cells expressing CD40L induced antigen‑presenting phenotypes, raised IL‑12 and IFN‑γ levels, expanded T‑cell counts, and correlated with reduced leukemia burden in a small clinical series (2000). In a pilot study of three children with X‑linked hyper‑IgM syndrome, subcutaneous rCD40L administered three times weekly for several months restored delayed‑type hypersensitivity responses and enhanced T‑cell cytokine production (2011). In neuroblastoma cell lines, CD40 engagement by rCD40L triggered caspase‑8‑mediated apoptosis (2004). Collectively, the data indicate that rCD40L can potentiate immune cell functions and, in limited human trials, improve certain immune defects.

Reported Benefits

Pre‑clinical studies demonstrate that rCD40L can drive B‑cell growth, class‑switch recombination, and synergize with other cytokines to boost antibody production. It activates CD4⁺ and CD8⁺ T cells, increasing IL‑2, IFN‑γ and TNF‑α output. Early clinical investigations suggest it can restore T‑cell‑mediated immunity in X‑linked hyper‑IgM patients and generate anti‑leukemia immune responses in CLL gene‑therapy settings. In tumor cell models, CD40 engagement can induce apoptosis.

Limitations of the Evidence

Most evidence derives from murine or cell‑culture systems; human data are limited to small, non‑randomised studies (three XHM patients, a single‑dose CLL trial). The ligand often requires cross‑linking or co‑stimulation with other cytokines for full activity, raising questions about potency in vivo. Long‑term efficacy, optimal dosing, and comparative effectiveness remain undefined, and no large‑scale clinical trials have been reported.

Safety Considerations

In the XHM pilot, subcutaneous rCD40L was well‑tolerated with no serious adverse events reported. The CLL gene‑therapy study noted no dose‑limiting toxicity, autoimmune cytopenias, or hemolytic anemia. Nonetheless, the potent immune activation raises theoretical risks of cytokine release, inflammation, or autoimmunity, and long‑term safety has not been established.

How It Is Administered

Experimental administration routes include subcutaneous injection (e.g., 0.03–0.05 mg/kg three times weekly in the XHM study) and intravenous delivery in pre‑clinical models. Formulations are typically soluble protein, sometimes presented on membrane vesicles or cross‑linked to enhance receptor clustering.

Routes of Administration

Goals & Uses

• Vaccine adjuvantVaccinologyModerate
• Platelet activation researchHematology / ResearchModerate
• Cancer immunotherapyOncologyModerate
• B cell immunodeficiency (Hyper-IgM syndrome)Immunology / Rare DiseaseLow

Contraindications

• History of thromboembolic eventsHematologicalHigh
• Severe cardiovascular diseaseCardiovascularHigh
• Active autoimmune diseaseAutoimmunityModerate

Adverse Effects

• Cytokine release syndromeImmunologicUnknownSystemic inflammatory response from immune activation
• Thromboembolic events (DVT, PE, arterial thrombosis)Hematological / VascularUncommon
• Flu‑like symptomsSystemicUnknown
• Injection site reactionsLocalCommon
• Fever / flu-like symptomsSystemicCommon
• Anti-drug antibody formationImmunologicalUncommon
• Cytokine release / inflammatory responseImmunologicalUncommon

Drug Interactions

• Antiplatelet agents (aspirin, clopidogrel)Low
• Immunosuppressive agents (e.g., corticosteroids, cyclosporine)Moderate
• Anticoagulants (warfarin, heparin, direct oral anticoagulants)Moderate

Population Constraints

• Pediatric patientsAgeRelative
• Patients with hypercoagulable statesHematologicalAbsolute
• Pregnant or breastfeeding womenReproductiveAbsolute
• Elderly patientsAgeRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalUnder clinical investigation in Europe
• United StatesInvestigationalInvestigational biologic; not FDA‑approved
• United KingdomInvestigationalNo MHRA approval. Follows similar status to EU; no approved therapeutic use.

No approved indication in any major jurisdiction. Early-phase clinical trials were halted or suspended due to serious thromboembolic events. Remains primarily a research-stage molecule. Some investigational use continues in ex vivo settings and as a vaccine adjuvant component.

Evidence & Sources

• Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines
  Journal ArticleLowMaliszewski CR, et al.1993-01-01T00:00:00.000000Z
• Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation
  Journal ArticleModerateKehry MR, Castle BE1994-01-01T00:00:00.000000Z
• Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand
  Journal ArticleModerateJain A, et al.2011-01-01T00:00:00.000000Z
• Immunogenicity of human neuroblastoma
  Journal ArticleModeratePrigione I, et al.2004-01-01T00:00:00.000000Z
• CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
  Journal ArticleModerateWierda WG, et al.2000-01-01T00:00:00.000000Z
• Recombinant CD40 ligand exerts potent biologic effects on T cells
  Journal ArticleLowFanslow WC, et al.1994-01-01T00:00:00.000000Z

Frequently Asked Questions